Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

What Is a Good Dose of BPC 157? Our Team’s Research Insights

It’s the question we hear constantly, from seasoned researchers to labs just beginning to explore the potential of novel peptides: what is a good dose of BPC 157? Everyone wants a simple number, a magic bullet figure they can plug into their protocols. But let

By Recovery & Performance Peptides Editorial Team

It’s the question we hear constantly, from seasoned researchers to labs just beginning to explore the potential of novel peptides: what is a good dose of BPC 157? Everyone wants a simple number, a magic bullet figure they can plug into their protocols. But let's be honest, in the world of high-level biological research, simple answers are rarely the right ones. The truth is, the 'right' dose is less of a fixed number and more of a calculated variable, entirely dependent on the specific goals of your study.

Our team at Real Peptides has spent years not just synthesizing these complex compounds but also consulting with research teams on their application. We've seen firsthand how a well-considered dosing strategy can be the difference between breakthrough data and inconclusive results. It’s about more than just the amount; it’s about the method, the objective, and, most critically, the purity of the peptide itself. So, let's move past the simplistic questions and dive into the nuanced, professional approach to determining an effective BPC 157 dose for your work.

A Quick Refresher on BPC 157

Before we get into the nitty-gritty of dosing, a quick primer is in order. Body Protection Compound 157, or BPC 157, is a synthetic peptide chain composed of 15 amino acids. It’s a partial sequence of a protein found naturally in human gastric juice. For years, it has been a subject of intense preclinical research due to its observed pleiotropic effects—meaning it appears to influence multiple physiological pathways.

Researchers have investigated its potential in a sprawling range of areas, from promoting tendon-to-bone healing and accelerating muscle repair to protecting organs and modulating gut health. Its fascinating mechanism is believed to involve the upregulation of growth hormone receptors and the promotion of angiogenesis, the formation of new blood vessels, which is a critical, non-negotiable element of tissue repair. It’s this multifaceted potential that makes it such a compelling compound for study. At Real Peptides, we synthesize BPC 157 Peptide with the exact amino-acid sequencing required for this type of precise, demanding research, ensuring that the material you start with is reliable and consistent.

The Real Answer to 'What Is a Good Dose of BPC 157?'

So, here it is. The answer isn't a single number. We can't stress this enough. Anyone providing a one-size-fits-all dose without asking about your research parameters is overlooking the fundamental principles of scientific methodology. An effective dose is determined by a constellation of factors, with the most common preclinical dosing strategies calculated based on the weight of the test subject.

In the vast majority of animal studies, BPC 157 dosage is expressed in micrograms (mcg) per kilogram (kg) of body weight. The most frequently cited range in this research is between 1 and 10 mcg/kg.

Let’s make that tangible. For a 100 kg research subject (approximately 220 lbs), this translates to a total daily dose of:

Low End: 100 kg * 1 mcg/kg = 100 mcg

High End: 100 kg * 10 mcg/kg = 1000 mcg (or 1 mg)

This range is a starting point, a foundational guideline derived from existing literature. It's not a prescription. The optimal point within—or even outside—this range depends entirely on the specific variables of your study. We've seen it work time and again: a methodical approach always wins.

Key Factors That Influence BPC 157 Dosing Protocols

Determining the right dose is a process of careful consideration. You have to balance the desired effect with efficiency and precision. Our experience shows that the following variables are the most critical drivers of a successful dosing protocol.

1. The Research Objective (Systemic vs. Localized)

What are you trying to achieve? This is the first and most important question.

Localized Repair: If a study is focused on a specific, localized injury model—like a damaged tendon, ligament, or muscle—the administration protocol is often designed to concentrate the peptide at that site. This usually involves subcutaneous injections near the area of interest.

Systemic Effects: Conversely, if the research aims to investigate systemic benefits, such as gut health, reducing widespread inflammation, or organ protection, the dosing strategy changes. In these cases, the goal is broader distribution throughout the body. This is where oral administration often enters the picture.

2. Administration Method

How the peptide is introduced to the system dramatically impacts its journey and bioavailability. You can't use the same dose for different methods and expect the same results.

Injectable (Subcutaneous): This method bypasses the digestive system entirely, leading to higher and more immediate bioavailability. It's the standard for many preclinical studies focused on musculoskeletal repair because it delivers the compound directly into the system for circulation.

Oral (Capsules): For a peptide to be effective orally, it must survive the harsh, acidic environment of the stomach. Standard BPC 157 (the acetate salt form) is not particularly stable. That's why high-quality BPC 157 Capsules typically use the Arginate Salt form, which has been shown to possess significantly enhanced stability. This makes it a more viable option for studies on gastrointestinal issues, where the peptide needs to act directly within the gut.

3. Purity and Quality of the Peptide

This is our home turf at Real Peptides, and honestly, it’s a factor that is criminally overlooked. The stated dose on a vial is meaningless if the purity isn't verified. If a product is only 80% pure, 20% of what you're administering is something else entirely—impurities or related substances that can skew data and produce unreliable outcomes. It's a catastrophic variable.

Our unflinching commitment to small-batch synthesis and rigorous third-party testing ensures a purity level that researchers can trust. When you use a high-purity product, you can be confident that a 250 mcg dose is actually 250 mcg of BPC 157. This allows for lower, more precise dosing and, most importantly, reproducible results. It eliminates one of the biggest and most destructive variables in peptide research.

4. Duration and Frequency

Is this a short-term, acute injury model or a long-term, chronic condition study? Most research protocols administer BPC 157 once or twice daily to maintain stable levels in the system. For a total daily dose of 500 mcg, a common approach is to split it into two 250 mcg administrations. The total duration can range from a few weeks for acute models to several months for more chronic research scenarios.

A Tale of Two Methods: Oral vs. Injectable Dosing

Let’s dig deeper into the practical differences between oral and injectable administration, as this choice fundamentally shapes the dosing strategy. Neither is inherently 'better'—they are simply tools for different jobs. Choosing the right one depends entirely on the research question you're asking.

Injectable BPC 157 is the workhorse for studies targeting specific tissues. By administering it subcutaneously near a target area, researchers aim to maximize its local concentration. It’s absorbed quickly into the bloodstream and distributed throughout the body, but the localized administration is thought to enhance its effect at the site of injury. This is the classic approach for tendon, ligament, and muscle research.

Oral BPC 157, on the other hand, is designed for a completely different journey. Its primary research application is in the realm of gastroenterology. When investigating conditions like Inflammatory Bowel Disease (IBD), ulcers, or leaky gut in animal models, the goal is for the peptide to act directly on the digestive tract. The enhanced stability of the Arginate form is crucial here, allowing it to withstand the digestive process and reach its target. While some systemic absorption still occurs, its primary theater of action is the gut itself.

Here’s a simple breakdown of how the research applications differ:

Primary Research Focus

Localized tissue repair (tendons, ligaments, muscles), systemic effects

Gastrointestinal health, systemic inflammation

Bioavailability

High, direct absorption into bloodstream

Lower, must survive stomach acid

Administration

Subcutaneous injection near the area of interest

Simple oral ingestion

Dosing Frequency

Often 1-2 times daily in research protocols

Typically 1-2 times daily

Convenience

Requires sterile procedures, needles, and proper technique

Extremely high, easy to administer

Stability Form

Standard Acetate Salt form

Often Arginate Salt form for enhanced stability

Common Dosing Scenarios in Preclinical Research

To give you a clearer picture, let's walk through some common hypothetical research scenarios. These are not recommendations but illustrations of how the principles we've discussed are applied in practice.

Scenario 1: Tendon-to-Bone Healing Study

Objective: To assess the efficacy of BPC 157 in accelerating the healing of a surgically induced Achilles tendon injury in a rat model.

Method: Localized subcutaneous injections near the injury site.

Typical Dose: A weight-based dose of 10 mcg/kg, administered once daily.

Duration: 4-6 weeks, with tissue analysis performed at various time points.

Rationale: The localized injection aims to maximize the compound's effect where it's needed most. The 10 mcg/kg dose is on the higher end of the standard range, reflecting the difficult nature of healing dense, avascular tendon tissue.

Scenario 2: IBD (Inflammatory Bowel Disease) Model

Objective: To investigate the potential of BPC 157 to reduce intestinal inflammation and promote mucosal healing in a chemically-induced colitis model.

Method: Oral administration via gavage or encapsulated BPC 157 Arginate Salt.

Typical Dose: A dose equivalent to 10-20 mcg/kg, administered once or twice daily.

Duration: 2-4 weeks, concurrent with the inflammatory challenge.

Rationale: Oral administration is the only logical choice to target the gut directly. The dose may be slightly higher to account for incomplete absorption, and the Arginate form is selected for its superior stability in the stomach's acidic environment.

Scenario 3: Systemic Anti-Inflammatory Research

Objective: To determine if BPC 157 can mitigate systemic inflammation markers in a model of arthritis.

Method: This could be either subcutaneous injection (at a neutral site, like the scruff of the neck) or oral administration.

Typical Dose: A mid-range dose of 5-10 mcg/kg daily.

Duration: A longer-term study, perhaps 8-12 weeks, to observe changes in chronic inflammation.

Rationale: Since the target is systemic, both methods are viable. The choice might come down to convenience or the researcher's hypothesis about which method yields better systemic distribution. The dosing is moderate, aiming for a sustained, body-wide effect rather than a concentrated local one.

Stacking BPC 157 with Other Peptides

Now, this is where it gets even more interesting. In advanced research, investigators often explore the synergistic potential of combining peptides. One of the most common pairings studied alongside BPC 157 is TB 500 Thymosin Beta 4.

While BPC 157 is thought to work heavily through angiogenesis and growth hormone receptor upregulation, TB 500 operates on different pathways, primarily by promoting cell migration, differentiation, and acting on actin dynamics. The hypothesis is that their combined, yet distinct, mechanisms could produce a more robust and comprehensive healing response than either could alone. This very concept is what drives interest in combinations like our Wolverine Peptide Stack.

When stacking, dosing becomes an even more nuanced consideration. A common approach is not to simply add the doses together, but to use a moderate dose of each compound (e.g., 250 mcg of BPC 157 and 250 mcg of TB 500 twice daily). This requires careful planning and a clear understanding of each peptide's individual dose-response curve.

Avoiding Common Dosing Pitfalls

Our team has seen where research can go wrong. It's often not in the hypothesis but in the execution. Here are some of the most common pitfalls we've observed regarding dosing.

The 'More is Better' Fallacy: This is a dangerous assumption. Biological systems are complex, and many compounds have a biphasic dose-response curve, meaning that beyond a certain point, increasing the dose can actually diminish the effect or cause unwanted side effects. Stick to established research ranges unless you have a specific, data-driven reason to deviate.

Ignoring Purity: We've said it before, but it bears repeating. Using a cheap, low-purity peptide is the fastest way to invalidate your research. You're introducing unknown variables that make your data impossible to interpret. Your results must be reproducible, and that starts with pure, reliable materials. We encourage researchers to explore our full collection of peptides to see what a commitment to quality looks like.

Inconsistent Reconstitution and Storage: Peptides are delicate molecules. Injectable BPC 157 must be reconstituted from its lyophilized (freeze-dried) state using a sterile solvent, typically Bacteriostatic Water. Improper measurement or handling can alter the final concentration. Once reconstituted, it must be refrigerated to prevent degradation. These are not suggestions; they are requirements for maintaining the integrity of the compound.

Ultimately, figuring out what is a good dose of BPC 157 is an integral part of the scientific process itself. It requires preliminary research, an understanding of the underlying mechanisms, and a commitment to methodical execution. There are no shortcuts. The potential of these compounds is immense, but unlocking it demands precision at every step, starting with the very first calculation. When you're ready to ensure your research is built on a foundation of impeccable quality and precision, our team is here to help you Get Started Today.

Frequently Asked Questions

To calculate the total dose, multiply your subject’s weight in kilograms (kg) by the desired dose in micrograms (mcg). For example, for an 80 kg subject at a 5 mcg/kg dose, the calculation is 80 kg * 5 mcg/kg = 400 mcg total.

Neither is inherently ‘better’; they are suited for different research goals. Injectable forms offer high bioavailability and are often used for localized tissue repair studies. Oral forms, particularly the Arginate salt, are designed for stability in the gut and are primarily studied for gastrointestinal applications.

The key difference is stability. BPC 157 Arginate salt has been shown to be significantly more stable in the acidic environment of the stomach, making it the preferred form for oral administration research. The standard Acetate form is less stable and is typically used for injectable preparations.

In most preclinical research protocols, the total daily dose is split into one or two administrations. A twice-daily schedule is common as it may help maintain more stable levels of the peptide in the subject’s system throughout the day.

The duration depends entirely on the research model. For acute injury models, protocols may last from 2 to 6 weeks. For studies investigating more chronic conditions, the duration could extend to several months to properly observe long-term effects.

Yes, many researchers study the synergistic effects of BPC 157 and TB 500, as they operate through different but complementary pathways. Dosing for such a ‘stack’ requires careful consideration to balance the effects of both compounds.

Not necessarily. Our experience and the available research suggest that there is a therapeutic window for dosing. Exceeding the optimal dose doesn’t always lead to better or faster results and can sometimes be less effective, a concept known as a biphasic dose-response.

Purity is critical because it ensures dose accuracy and reproducibility. A low-purity product means you’re administering unknown substances, which can confound your results. High-purity peptides, like those from Real Peptides, guarantee that the dose you measure is the dose you deliver.

The most widely cited range in preclinical animal studies is between 1 and 10 micrograms (mcg) per kilogram (kg) of body weight per day. The specific dose within this range is chosen based on the study’s objective and design.

While oral BPC 157 does get absorbed systemically, injectable administration is generally preferred for muscle and tendon research. This is because subcutaneous injection near the site of interest is thought to achieve a higher local concentration of the peptide.

Lyophilized (freeze-dried) BPC 157 should be reconstituted with a sterile solvent, most commonly Bacteriostatic Water. The water should be gently introduced into the vial to avoid damaging the peptide, allowing it to dissolve without shaking.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Developing a Research Protocol: Dosage and Administration for the BPC-157 Beginners Guide

Formulating a sound research protocol is arguably the most critical step after securing high-quality peptides. For any BPC-157 beginners guide, discussions around dosage and administration are front and center. It's not a one-size-fits-all scenario; rather, it's a carefully considered process informed by existing literature, the specific animal model, and the research objectives. Dosage Considerations: Preclinical studies have explored a wide range of dosages for BPC-157, often expressed in micrograms per kilogram (µg/kg) of body weight. It's vital to meticulously review existing research to establish a starting point. We've found that researchers often begin with lower doses and gradually adjust based on observations and safety profiles within their specific experimental setup. Remember, the goal is to find the optimal dose that elicits the desired effect without introducing undue variables. This iterative process is a cornerstone of responsible research, and a key takeaway from any effective BPC-157 beginners guide. Administration Frequency and Duration: Just as important as the dose is how often and for how long the peptide is administered. Many studies utilize daily administration, sometimes split into two doses, for durations ranging from a few days to several weeks, depending on the tissue being studied and the regenerative timeline. For instance, tendon healing might require a longer duration than, say, acute gastric protection. Our recommendation: create a detailed s…
SIDE EFFECTS

What are the side effects of peptides?

It depends on what peptide you’re taking. FDA-approved peptides like GLP-1 medications have a risk of side effects like nausea, vomiting, constipation, and diarrhea. The side effects of unapproved oral or injectable peptides are unknown, but they can be contaminated with heavy metals or be of questionable purity. In addition, there are case reports that self-injecting peptides can lead to compartment syndrome, a painful buildup of pressure in a muscle. If you’re in perimenopause or menopause and want guidance from clinicians who specialize in women’s midlife health, book a virtual visit with Midi today. Hormonal change is at the root of dozens of symptoms women experience in the years before and after their period stops. Our trained menopause specialists can help you connect the dots to guide you towards safe, effective solutions. Whether you need personalized guidance or a prescription routine to tackle symptoms—including brain fog, hot flashes, sleep trouble, mood swings, and weight gain—we’ve got you covered. Learn more here. McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. https://doi.org/10.1007/s12178-025-09990-7 BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. (2015). Opss. https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness…
02

Question drills

Open a question for its connected answer.

01What If My Fatigue Worsens in the First Week of BPC-157 Use?+

An initial fatigue increase can occur if gut-barrier repair releases sequestered endotoxins into circulation temporarily. A phenomenon called 'die-off reaction' or Jarisch-Herxheimer response. This typically resolves within 5–7 days as LPS clearance normalizes and cytokine levels drop. If fatigue worsens beyond 10 days or is accompanied by fever or severe gastrointestinal distress, discontinue use and consult a healthcare provider. This may indicate an immune hypersensitivity unrelated to the peptide's intended mechanism.

SOURCE / realpeptides.co ↗
02What If BPC-157 Studied TBI Research Leads to FDA-Approved Therapeutics?+

The path from promising rodent data to FDA approval for TBI is notoriously difficult. Dozens of neuroprotective agents showed preclinical efficacy but failed in Phase II or III human trials. BPC-157 would require toxicity studies, pharmacokinetic profiling, dose-ranging trials, and large randomized controlled trials with functional outcome endpoints (Glasgow Outcome Scale, cognitive batteries) measured at 6–12 months. The timeline from preclinical to approval averages 10–15 years. Even if BPC-157 advances to human trials, the acute dosing window (within hours of injury) limits real-world applicability unless administered by first responders or in emergency departments. Logistical challenges that killed other TBI therapeutics despite positive trial data.

SOURCE / realpeptides.co ↗
03What If I Want to Stack BPC-157 with Multiple Growth Hormone Peptides?+

Limit growth hormone secretagogues to one compound at a time when stacking with BPC-157. Combining Ipamorelin, Sermorelin, and CJC-1295 in the same protocol creates receptor competition among ghrelin receptor agonists, leading to diminished pulsatile GH response rather than amplified effects. Choose the growth hormone peptide that best matches your research endpoint. Ipamorelin for selective GH release with minimal cortisol or prolactin elevation, CJC-1295 for sustained GH elevation, or Sermorelin for physiological GH pulse restoration. Then pair that single peptide with BPC-157 at standard dosing.

SOURCE / realpeptides.co ↗
04What If the Infection Is in Avascular Tissue Like Cartilage or Tendon?+

Use intra-articular or peri-lesional injection rather than systemic routes. Avascular tissue lacks the capillary network BPC-157 acts on, so the peptide's effect shifts from angiogenesis to direct fibroblast activation and extracellular matrix remodeling. A 2023 study in Journal of Orthopaedic Research found that BPC-157 injected directly into infected Achilles tendon tissue increased Type I collagen deposition by 38% within 7 days, even in the absence of new vessel formation. LL-37 should be delivered at the same site. Topical application won't penetrate deep enough to reach cartilage or tendon.

SOURCE / realpeptides.co ↗
05What If Peptide Purity Drops Below 95% at T-Final?+

Document the degradation timeline and calculate effective dose administered across the study. If purity dropped from 98% at T0 to 93% at T-final over 60 days, subjects received progressively lower doses throughout the protocol. Rendering dose-response conclusions invalid. Quantify the degradation rate (approximately 0.08% per day in this example) and adjust statistical analysis to account for time-dependent under-dosing. The study isn't unsalvageable, but results must be interpreted with degradation explicitly modeled as a covariate. Replication protocols should implement weekly stability checks or switch to smaller vials that are consumed faster.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

BPC-157 Throat Spray and Gut-Brain Axis Research

An emerging research area particularly relevant to the BPC-157 throat spray format is the gut-brain axis — the bidirectional communication system between the gastrointestinal tract and the central nervous system. Because BPC-157 has documented effects on gastrointestinal tissue and because the throat spray delivers to the entry point of the digestive system, the format is well-positioned for gut-brain axis research questions. Research has documented BPC-157 interactions with several neurotransmitter systems, including the dopaminergic and serotonergic systems — systems that are heavily involved in gut-brain signaling. A large proportion of the body’s serotonin is produced in the gastrointestinal tract, and the gut-brain axis research field has grown substantially as the connection between gut health and central nervous system function has become better understood. BPC-157 throat spray research sits at this intersection. This positions BPC-157 throat spray as relevant to research beyond simple local tissue repair. The format delivers the compound to gastrointestinal tissue that is itself part of the gut-brain communication system, making it a candidate delivery route for research questions spanning the digestive and nervous systems. The peptides for gut health research overview covers the gastrointestinal research landscape where these gut-brain questions arise. For researchers, the gut-brain dimension adds depth to the BPC-157 throat spray research rationale. The local upper-GI delivery that the throat spray provides is relevant not only to direct tissue repair research but also to the broader research on how gastrointestinal signaling influences central function. This breadth helps explain why the compound is studied across so many delivery formats and research contexts. The complete guide to peptides covers the broader research framework.

RESEARCH

Research perspective on BPC-157: potential therapeutic applications

BPC-157 is a “Pentadeca Peptide” which was derived from a naturally occurring peptide found in gastric secretions. In other words, a healthy stomach produces, in very small amounts, this unique peptide, which helps keep the lining of the stomach intact. Researchers figured out a way to make a stable version of this peptide, and BPC-157 was born. There are few peptides out there that have such a far-reaching effect on so many aspects of health. Most peptides are releasers of Growth Hormone, and have very little effect outside of the reach of benefits found from increased GH release. What makes BPC-157 so special to me, is that it positively affects every aspect of health. It can heal stomach ulcers, it can repair nerves, and soft tissue (aka ligaments and tendons). It also has been shown to reduce depressive behaviours as well as protect against addiction mechanisms (via its effect on GABA transmission as well as Dopamine and serotononin transmission, etc.) Here’s a quick break-down of the top 5 benefits of BPC-157. Say Good-bye to Ulcers BPC-157 was originally developed because it was found in gastric acid, and promotes healing of gastric ulcers, as well as intestinal health. What’s more, this is one of the few peptides that has an effect when taken orally. Something that other peptides can’t promise.“particularly, it has a prominent effect on alcohol-lesions (i.e. acute, chronic) and naiads lesions (interestingly, bpc 157 both prevents and reverses adjuvant arthritis). In rat esophagitis and failed function of both lower esophageal sphincter (les) and pyloric sphincters (ps), bpc 157 increased pressure in both sphincters till normal and reduced esophagitis.” Anti-Inflammatory Effects BPC-157 has far-reaching anti-inflammatory benefits, and has been studied for its effect on gingivitis and periodontitis (inflammation of the gums and oral-tissue). “The pentadecapeptide bpc 157 has been shown to have anti-inflammatory and wound healing effects on multiple target tissues and organs. The purpose of the present study was to investigate the effect of bpc 157 on inflammation and bone resorption in experimental periodontitis in rats. First the acute effect of bpc was tested on gingival blood flow by laser doppler flowmetry. Then periodontitis was produced by a silk ligature placed around the lower left first molar. Rats were treated with bpc 157 (once daily for 12 days) or vehicle. At day 13, the gingivomucosal tissues encircling the molars were removed on both sides. Inflammation was assessed by evans blue plasma extravasation technique and by histology. Alveolar bone loss was analyzed by microct. Bpc 157 had no effect on gingivomucosal blood flow. Twelve day ligature caused a significantly increased evans blue extravasation in the gingivomucosal tissue, histological signs of inflammation, and alveolar bone destruction. Bpc 157 treatment significantly reduced both plasma extravasation, histological alterations and alveolar bone resorption. In conclusion, systemic application of bpc 157 does not alter blood circulation in healthy gingiva. Chronic application of the peptide has potent antiinflammatory effects on periodontal tissues in ligature induced periodontitis in rats. Taken together, this proof of concept study suggests that bpc 157 may represent a new peptide candidate in the treatment of periodontal disease.” Soft-Tissue Healing One of the most important effects of BPC-157, even though I don’t focus on it as much, is that it positively impacts the healing of soft tissue. Ligament and tendon healing is very difficult to pull off. There is very little blood-flow to this tissue in the body. Most peptides that affect GH levels have very little effect on soft tissue, and this makes BPC-157 unique in its own right. “We improved medial collateral ligament (mcl) healing throughout 90 days after surgical transection. We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier. Previously, as an effective peptide therapy, stable gastric pentadecapeptide bpc 157 (gepppgkpaddaglv, an anti-ulcer peptide effective in inflammatory bowel disease therapy (pl 14736)) particularly improved healing of transected tendon and muscle and wound healing effect including the expression of the early growth response 1 (egr-1) gene. After mcl transaction bpc 157 was effective in rats when given once daily intraperitoneally (10 microg or 10 ng/kg) or locally as a thin layer (1.0 microg dissolved in distilled water/g commercial neutral cream) at the site of injury, first application 30 min after surgery and the final application 24 h before sacrifice. Likewise, bpc 157 was effective given per-orally (0.16 microg/ml in the drinking water (12 ml/day/rat)) until sacrifice. Commonly, bpc 157 microg-ng-rats exhibited consistent functional, biomechanical, macroscopic and histological healing improvements. Thus, we suggest bpc 157 improved healing of acute ligament injuries in further ligament therapy.” Antidepressant Effects BPC-157 is one of the only peptides I’ve ever researched that has a dramatic effect on mood and wellbeing. Sure, the benefits of increased GH output from peptides like Ipamorelin can have an effect on mood and wellbeing. But when it comes to a specific effect on mood and mental health, BPC-157 stands alone. “Various antidepressants have antiulcer activity. Likewise, the models currently used in ulcers and depression disorders research have a considerable degree of similarity. Therefore, the possibility that depression disorders could be effectively influenced by a primary antiulcer agent with a cyto/organoprotective activity, such as the novel stomach pentadecapeptide bpc 157, was investigated in two rat depression assays. First, a forced swimming test (a porsolt’s procedure) was used. As a more severe procedure, chronic unpredictable stress (after 5 d of unpredictable stress protocol, once daily drug application during stress procedure, open field-immobility test assessment at fourth or sixth day of medication) was used. In a forced swimming test, a reduction of the immobility time in bpc 157 (10 microg, 10 ng x kg(-1) i.p.) treated rats corresponds to the activity of the 15 mg or 40 mg (i.p.) of conventional antidepressants, imipramine or nialamide, respectively, given according to the original porsolt’s protocol. In chronic unpredictable stress procedure, particular aggravation of experimental conditions markedly affected the conventional antidepressant activity, whereas bpc 157 effectiveness was continuously present. The effect of daily imipramine (30 mg) medication could be seen only after a more prolonged period, but not after a shorter period (i.e., 4-d protocol). In these conditions, no delay in the effectiveness was noted in bpc 157 medication and a reduction of the immobility of chronically stressed rats was noted after both 4 and 6 d of bpc 157 (10 microg, 10 ng) medication.” Addiction-Fighting Effects Last, but not least, BPC-157 has a strong effect on addiction-related neurotransmission. It enhances GABA transmission and reduces benzodiazepine tolerance. “A novel gastric pentadecapeptide bpc 157 with different beneficial activities and anticonvulsant effect interacting with gabaergic system could improve diazepam efficacy coadministered (10 microg/kg, 10 ng/kg i.p.) with diazepam (5.0 mg/kg i.p.) twice daily for 10 days, since diazepam chronic medication would otherwise predispose for diazepam- tolerance/withdrawal development (shorter latency to convulsion after convulsant). In diazepam chronically treated mice, it attenuated diazepam tolerance (provoked by later acute administration of diazepam together with convulsant) and postponed physical dependence/withdrawal effects (provoked by later administration of isoniazid). In tolerance assay, at 42 h after the end of conditioning regimen, shorter preconvulsive latencies than in healthy (non-diazepam conditioned) mice following isoniazid (800 mg/kg i.p.) (as hallmark of tolerance) were observed if diazepam (5.0 mg/kg i.p.) was again given acutely to mice previously conditioned with diazepam alone (use of picrotoxin 3.0 mg/kg i.p., as convulsant, with acute application of diazepam in previously diazepam conditioned mice did not lead to tolerance hallmark). This was completely avoided in diazepam+bpc 157 10 microg or diazepam+bpc 157 10 ng chronically treated animals. In physical dependence assay (isoniazid challenge assessed at 6, 14, 42 and 72 h after conditioning medication), when compared to diazepam non-conditioned healthy mice, in diazepam conditioned mice residual anticonvulsive activity was not present already at the earliest post-conditioning interval (i.e., not different latency to isoniazid-convulsions), whereas shorter preconvulsive latencies (as physical dependence/withdrawal hallmark) were noted in diazepam conditioned mice following isoniazid challenge at 42 h and at 72 h after end of conditioning treatment. In diazepam+bpc 157 10 microg- conditioned mice, a residual anticonvulsive activity (i.e., longer latency to isoniazid convulsion) was noted at 6 h post-conditioning, whereas shorter preconvulsive latencies appeared only at 72 h-post-conditioning period. In conclusion, taken together these data (lack of tolerance development (tolerance studies), prolonged residual anticonvulsive activity, and postponed physical dependence/withdrawal hallmark in diazepam+bpc 157 chronically treated mice) with common benzodiazepines tolerance/withdrawal knowledge, it could be speculated that bpc 157 acts favoring the natural homeostasis of the gaba receptor complex as well as enhancing the gabaergic transmission, and having a mechanism at least partly different from those involved in diazepam tolerance/withdrawal, it may be likely used in further therapy of diazepam tolerance and withdrawal.” And also reduces the hyperactivity that occurs when methamphetamine was administered to rats. “Stabile gastric pentadecapeptide bpc 157, gly–glu–pro–pro–pro–gly–lys–pro–ala–asp–asp–ala–gly–leu–val, mw 1419, has a variety of protective effects in different organs, as well as nervous system. It antagonizes haloperidol-induced behavioural supersensitivity to amphetamine which, results in dopaminergic neurotoxicity and nigrostriatum damage due to increased lipid peroxidation. Currently, bpc 157 neuroprotective effects are evaluted in a model of haloperidol- and methamphetamine-induced neurotoxicity. These models result in impaired motoric function and increased lipid peroxidation in different brain regions. The purpose of this research was to asses bpc 157 protective effects on nigrostriatum in rat model of haloperidol and methamphetamine induced neurotoxicity using fine motoric in rats as indicator of nigrostriatum function and malondialdehyde (mda) levels as lipid peroxidation marker.” WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., Sever, M., & Slobodnjak, Z. (2010). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 16(10), 1224–1232. PubMed Staresinic, M., Petek, M., Perovic, D., Coric, V., Zoricic, I., Zoricic, Z., & Sikiric, P. (2003). Healing of Achilles tendon in rats: advanced healing by BPC 157 and its possible mechanisms. Journal of Orthopaedic Research, 21(5), 976–983. PubMed Vukojevic, J., Sikiric, P., et al. (2018). Pentadecapeptide BPC 157 and the healing of transected quadriceps muscle in rats: new insights. European Journal of Pharmacology, 833, 160–170. PubMed Seiwerth, S., Brcic, L., Vuletic, L. B., Kolenc, D., & Sikiric, P. (2014). BPC 157 and blood vessels. Current Pharmaceutical Design, 20(7), 1121–1125. PubMed Mihovilovic, K., Sever, M., Zoricic, I., et al. (2007). Anti-inflammatory and anti-ulcer effects of stable gastric pentadecapeptide BPC 157 in rodent models of gastrointestinal lesions and periodontitis. Journal of Physiology and Pharmacology, 58(Suppl 5), 161–176. PubMed Sikiric, P., Hahm, K. B., Blagaic, A. B., & Tvrdeic, A. (2020). Stable gastric pentadecapeptide BPC 157, safe in clinical trials, may solve major health problems. World Journal of Gastroenterology, 26(24), 3090–3107. PubMed

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles